UBS analyst Mark Yokoyama initiated coverage of SanBio (SNBIF) with a Neutral rating and 2,000 yen price target The company’s platform expansion offers long term upside but limited near term vaIue, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNBIF: